Generics Makers Seek To Sell Drugs Below Wholesale To India’s Poor
This article was originally published in PharmAsia News
Executive SummaryIndian generics makers are pressing their government to be included as suppliers of drugs included in a national program to make low-cost drugs available to the poor. The program, Jan Aushadhi, consists of a drugstore chain able to negotiate with drug makers to provide drug prices well below wholesale. The Department of Pharmaceuticals is considering a list of firms willing to be suppliers, include 76 generics makers to date. Jan Aushadhi plans to announce soon the drugs it will supply, currently numbering 400. (Click here for more
You may also be interested in...
Brands unfairly maligned by powerful influencers, strictly on behalf of paying competitors, could have occasion to broach the subject with the US Federal Trade Commission, which seeks comment on its “Endorsement Guides” in an increasingly complex and competitive, digitized advertising environment.
At least one FTC commissioner seems convinced that the agency’s Enforcement Guides are ripe for an update to address unscrupulous influencer marketing practices. Democrat Rohit Chopra proposes their codification into formal rules that would make violators liable for civil penalties and damages under FTC Act provisions.
The US agency has suspended all routine surveillance inspections in China through the end of March because of coronavirus fears, commissioner Stephen Hahn announced late on 14 February. Despite expecting medical product shortages, Hahn said the agency is being proactive: “We are not waiting for drug and device manufacturers to report shortages to us” before acting. The timing of Hahn’s statement – at 6 p.m. EST on a Friday, at the beginning of a three-day US holiday weekend – suggests he isn’t particularly excited to share the information.